BACKGROUND: European studies have shown that itch is a widespread symptom, yet little is known about its frequency in the United States. OBJECTIVE: We sought to describe ambulatory care visits to clinicians in the United States for which itch was coded as a patient symptom. METHODS: This study uses retrospective data from the National Ambulatory Medical Care Survey from 1999 through 2009. RESULTS: Itch was coded as a symptom for an average of 7 million visits per year or approximately 1% of all outpatient visits, which was nearly 40% of the number of visits for the symptom of low back pain. Patients seen in visits for itch were more likely to be black or Asian than other patients (20% vs 14%). They were also more likely than other patients to receive a new medication (68% vs 36%) and were over twice as likely to receive 2 or more new medications (31% vs 14%). LIMITATIONS: Secondary data sets may not optimally capture patient reports and some of the procedures or medications may have been ordered for reasons other than itch. CONCLUSION: Visits to clinicians for itch represent a sizeable proportion of ambulatory care visits in the United States, and research on the epidemiology, treatments, and causes of itch should be a priority.
BACKGROUND: European studies have shown that itch is a widespread symptom, yet little is known about its frequency in the United States. OBJECTIVE: We sought to describe ambulatory care visits to clinicians in the United States for which itch was coded as a patient symptom. METHODS: This study uses retrospective data from the National Ambulatory Medical Care Survey from 1999 through 2009. RESULTS:Itch was coded as a symptom for an average of 7 million visits per year or approximately 1% of all outpatient visits, which was nearly 40% of the number of visits for the symptom of low back pain. Patients seen in visits for itch were more likely to be black or Asian than other patients (20% vs 14%). They were also more likely than other patients to receive a new medication (68% vs 36%) and were over twice as likely to receive 2 or more new medications (31% vs 14%). LIMITATIONS: Secondary data sets may not optimally capture patient reports and some of the procedures or medications may have been ordered for reasons other than itch. CONCLUSION: Visits to clinicians for itch represent a sizeable proportion of ambulatory care visits in the United States, and research on the epidemiology, treatments, and causes of itch should be a priority.
Authors: Nisha S Desai; Gabriele B Poindexter; Yvette Miller Monthrope; Sandra E Bendeck; Robert A Swerlick; Suephy C Chen Journal: J Am Acad Dermatol Date: 2008-06-11 Impact factor: 11.527
Authors: I Cenzer; N Nkansah-Mahaney; M Wehner; M M Chren; T Berger; K Covinsky; K Berger; K Abuabara; E Linos Journal: Br J Dermatol Date: 2019-07-21 Impact factor: 9.302
Authors: Jonathan I Silverberg; Robert W Kantor; Prarthana Dalal; Catherine Hickey; Sara Shaunfield; Karen Kaiser; Jin-Shei Lai; David Cella Journal: Am J Clin Dermatol Date: 2018-10 Impact factor: 7.403
Authors: Lisa L Zhai; Kevin T Savage; Connie C Qiu; Annie Jin; Rodrigo Valdes-Rodriguez; Nicholas K Mollanazar Journal: Medicines (Basel) Date: 2019-06-29